White film coated tablets are biconvex, apple-shaped, embossed with "ARCOXIA 90" on one side, and embossed with "202" on the other.
active substance: etoricoxib 90.0 mg; excipients: calcium dihydrogen phosphate 90.0 mg, microcrystalline cellulose 111.0 mg, croscarmellose sodium 6.0 mg, magnesium stearate 3.0 mg; film coating of the tablet: Opadry II White 39K18305 12.0 mg, which includes: lactose monohydrate 35.0% (wt.), hypromellose 33.0% (wt.), titanium dioxide .0% (wt.), triacetype 8.0% (weight); carnauba wax 0.03 mg.
NSAIDs. A selective COX-2 inhibitor, in therapeutic concentrations, blocks the formation of prostaglandins and has an anti-inflammatory, analgesic and antipyretic effect. Selective inhibition of COX-2 is accompanied by a decrease in the severity of clinical symptoms associated with the inflammatory process, while there is no effect on platelet function and gastrointestinal mucosa. Etoricoxib has a dose-dependent effect of inhibition of COX-2, without affecting COX-1 when used in a daily dose of up to 150 mg. Arcoxia® does not affect the production of prostaglandins in the gastric mucosa and bleeding time. In the studies conducted, there was no decrease in the level of arachidonic acid and platelet aggregation caused by collagen.
Symptomatic therapy of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, pain and inflammation associated with acute gouty arthritis. Short-term therapy of moderate acute pain after dental surgery.